Analysis of network based co-expression modules for Alzheimer's disease
Prerna Dua1, Sonali Bais, Walter J Lukiw
1Dept. of Health Informatics and Information Management, Louisiana Tech University, Ruston, LA, USA.
Studies in Health Technology and Informatics
|August 8, 2013
Summary
This study compares Mutual Information and Pearson Correlation for Alzheimer's disease gene networks, finding Mutual Information better identifies biologically relevant gene modules and potential drug targets.
Area of Science:
- Genomics
- Computational Biology
- Neuroscience
Background:
- Alzheimer's disease (AD) research has intensified, yet pathogenic factors remain unclear.
- Understanding gene expression in AD is crucial for identifying disease mechanisms.
Purpose of the Study:
- To compare Mutual Information (MI) and Pearson Correlation Coefficient (PCC) for constructing gene co-expression networks in Alzheimer's disease.
- To evaluate the ability of MI-based networks to capture more biologically significant gene dependencies than PCC-based networks.
Main Methods:
- Utilized hippocampal gene expression data from 22 AD patients.
- Developed a framework for comparative analysis of MI and PCC in gene co-expression network construction.
- Employed a parameter-free module discovery algorithm and validated modules using Jaccard index and biomedical literature search.
Main Results:
- Mutual Information-based gene co-expression networks identified more biologically significant functional modules compared to Pearson Correlation Coefficient.
- Validated modules showed strong concordance with existing biological modules.
- Identified potential drug interdiction pathways and therapeutic targets for Alzheimer's disease.
Conclusions:
- Mutual Information is a superior measure for inferring biologically relevant gene co-expression networks in Alzheimer's disease research.
- The framework provides a robust method for discovering functional modules and potential therapeutic targets in complex diseases.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...